Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer is the tenth most common cancer type worldwide. Urothelial carcinoma is the
most common type of bladder cancer and accounts for 90% of bladder cancer cases in the …

Background Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved
for the treatment of locally advanced or metastatic urothelial carcinoma in adults with …

Background Previous randomised controlled trials comparing bladder preservation with
radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual …

The implementation of cisplatin-based neoadjuvant chemotherapy (NAC) plays a key role in
conjunction with surgical resection in preventing bladder cancer progression and …

Background Urothelial carcinoma (UC) is the most common pathological type of bladder
cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC …

Abstract Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-
checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle …

Background The standard of care treatment for muscle-invasive bladder cancer (MIBC) is
radical cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the …

Purpose HER2 alterations are potential candidates for targeted treatments in metastatic
urothelial/bladder cancer (mUC). ERBB2 gene amplification and mutations are found in …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …